RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-3.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.3B
AUM Growth
+$2.3B
(-5.7%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
4.81%
Top 10 Holdings %
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$40.1M |
| 2 |
DexCom
DXCM
|
$39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$32.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
$31.2M |
Top Sells
| 1 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$38.9M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$37M |
| 3 |
Pliant Therapeutics
PLRX
|
$25.3M |
| 4 |
Akero Therapeutics
AKRO
|
$22.5M |
| 5 |
Amicus Therapeutics
FOLD
|
$21.1M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
The Oncology Institute
TOI
$303M
| $216K | 0.01% |
318,082
-1,265,076
| -80% | -$858K |
|
77
Bioventus
BVS
$472M
| – | – |
-535,950
| Closed | -$1.4M |
|
78
Ionis Pharmaceuticals
IONS
$9.65B
| – | – |
-266,187
| Closed | -$10.1M |
|
79
Revolution Medicines
RVMD
$7.41B
| – | – |
-625,000
| Closed | -$14.9M |
|
|
ONEM
80
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| – | – |
-2,326,625
| Closed | -$38.9M |
|